# US 2012/0253188 A1 · Reducing risk of complications associated with tissue ablation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253188 A1
- Document ID: US20120253188A1
- Status: Published application
- Kind: A1
- Application number: 13/434,750
- Filed: 2012-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: University of Rochester
- Inventors: George A. HOLLAND
- Web page: https://patentgrep.com/patent/US20120253188A1

## CPC

- A61B 6/12: Arrangements for detecting or locating foreign bodies
- A61B 8/085: {for locating body or organic structures, e.g. tumours, calculi, blood vessels, nodules}
- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61B 18/12: by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B 6/481: {involving the use of contrast agents}
- A61B 6/508: {for non-human patients}
- A61B 8/481: {involving the use of contrast agents, e.g. microbubbles introduced into the bloodstream}
- A61B 18/1815: {using microwaves}
- A61B 2018/00577: {Ablation}
- A61B 2018/00613: {Irreversible electroporation}
- A61B 2018/00791: {Temperature}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Methods and systems are described that reduce risks of hematologic, metabolic, and renal complications in a mammal, such as a human, undergoing tissue ablation. One such method includes inserting a probe into a mammal and ablating abnormal tissue in the mammal by emitting a first amount of energy from the probe. In some embodiments, after emitting the first amount of energy, a method can include denaturing proteins released from cells in the abnormal tissue by emitting a second amount of energy from at least one of the first probe or a second probe inserted into the mammal. Furthermore, some embodiments can be implemented such that during or after the emitting the energy from a probe, a composition is administered to the mammal in an effective amount to denature proteins released from cells in the abnormal tissue.

## Claims

### Claim 1

A method for reducing a risk of hematologic and/or metabolic complications in a mammal undergoing tissue ablation, comprising:
inserting a first probe into a mammal;
ablating abnormal tissue in the mammal by emitting a first amount of energy from the first probe; and
after emitting the first amount of energy, denaturing proteins released from cells in the abnormal tissue by emitting a second amount of energy from at least one of the first probe or a second probe inserted into the mammal.

### Claim 2 (depends on 1)

The method of claim 1, further comprising monitoring heating of a region of tissue comprising the abnormal tissue.

### Claim 3 (depends on 2)

The method of claim 2, wherein the monitoring heating occurs during emission of the first amount of energy.

### Claim 4 (depends on 2)

The method of claim 2, wherein the monitoring is performed with a temperature sensor placed in the mammal.

### Claim 5 (depends on 2)

The method of claim 2, wherein the monitoring is performed by imaging with at least one of x-ray, ultrasound, computed topography (CT) or magnetic resonance imaging (MRI).

### Claim 6 (depends on 2)

The method of claim 2, wherein the monitoring heating occurs during emission of the second amount of energy.

### Claim 7 (depends on 1)

The method of claim 1, wherein the second amount of energy is emitted at least until the temperature of a region of tissue reaches about 42° C. to about 60° C. such that proteins released from cells in the abnormal tissue can be denatured.

### Claim 8 (depends on 7)

The method of claim 7, wherein the second amount of energy is emitted until the temperature of the region of tissue reaches about 42° C. to about 60° C. for at least one hour.

### Claim 9 (depends on 1)

The method of claim 1, wherein the second amount of energy is emitted such at least until the temperature of a region of tissue reaches about 62° C.

### Claim 10

A method of reducing a risk of hematologic and metabolic complications in a mammal undergoing tissue ablation, comprising:
inserting a probe into a mammal;
ablating abnormal tissue in the mammal by emitting energy from the probe; and
administering a composition to the mammal in an effective amount to denature proteins released from cells in the abnormal tissue.

### Claim 11 (depends on 10)

The method of claim 10, wherein the administering occurs during the emitting.

### Claim 12 (depends on 10)

The method of claim 10, wherein the composition is administered through the probe.

### Claim 13 (depends on 10)

The method of claim 10, wherein the administering comprises infusing a contrast agent into the mammal.

### Claim 14 (depends on 13)

The method of claim 13, wherein the contrast agent is heated before the administering.

### Claim 15 (depends on 13)

The method of claim 13, wherein the contrast agent is administered with saline, wherein with saline is hypertonic relative to a concentration of saline in the mammal's circulation.

### Claim 16 (depends on 10)

The method of claim 10, wherein the composition comprises a denaturing agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the denaturing agent comprises at least one of a chaotropic agent, a lyotropic agent, an organic denaturant, or a detergent.

### Claim 18 (depends on 17)

The method of claim 17, wherein the chaotropic agent is urea.

### Claim 19 (depends on 10)

The method of claim 10, further comprising monitoring the denaturation of proteins released from a region of tissue comprising the abnormal tissue.

### Claim 20 (depends on 10)

The method of claim 10, wherein the effective amount is effective to reduce a risk in a mammal of at least one of disseminated intravascular coagulation (DIC), tumor lysis syndrome, infection, bleeding, hemorrhage, tumor seeding, or multisystem organ failure.
